Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.

Cytomegalovirus (CMV) infections in liver transplant recipients are common and result in significant morbidity and mortality. Intravenous ganciclovir or oral valganciclovir are the standard treatment for CMV infection. The present study investigates the efficacy of oral valganciclovir in CMV infecti...

Full description

Bibliographic Details
Main Authors:	Jong Man Kim, Choon Hyuck David Kwon, Jae-Won Joh, Young Eun Ha, Dong Hyun Sinn, Gyu-Seong Choi, Kyong Ran Peck, Suk-Koo Lee
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4420490?pdf=render

Similar Items

Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.
by: Hyeyoung Lee, et al.
Published: (2017-01-01)

A succinct synthesis of valganciclovir hydrochloride – A cytomegalovirus (CMV) retinitis inhibitor
by: Karrothu Srihari Babu
Published: (2011-01-01)

Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors
by: Posner Gary H, et al.
Published: (2011-01-01)

Role of Valganciclovir in Children with Congenital CMV Infection: A Review of the Literature
by: Davide Pata, et al.
Published: (2023-07-01)

A Systematic Review and Meta-analysis of Optimized CMV Preemptive Therapy and Antiviral Prophylaxis for CMV Disease Prevention in CMV High-Risk (D+R-) Kidney Transplant Recipients
by: Lakshin Kumar, et al.
Published: (2023-08-01)

Colonic perforation in a kidney recipient with Cytomegalovirus (CMV) colitis
by: F Oliaei, et al.
Published: (2005-01-01)

Cytomegalovirus (CMV) Infection and Latency
by: Christine M. O’Connor
Published: (2021-03-01)

Effect of ageing on CMV-specific CD8 T cells from CMV seropositive healthy donors
by: Alonso Corona, et al.
Published: (2009-08-01)

A Novel Case of CMV Resistance to Valganciclovir and Maribavir in a Renal Transplant Patient
by: Helen Pearce, et al.
Published: (2024-01-01)

Challenges in Cytomegalovirus (CMV) Retinitis Management
by: Denisa Rosati, et al.
Published: (2019-09-01)

Cytomegalovirus (CMV) epitope-specific CD4(+) T cells are inflated in HIV(+) CMV(+) subjects
by: Abana, CO, et al.
Published: (2017)

Monitoring of cytomegalovirus (CMV) infection in solid organ transplant recipients: quantitation of CMV DNAemia by two real-time polymerase chain reaction assays
by: Angela Chiereghin, et al.
Published: (2016-10-01)

Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMV‐specific T cells
by: Helen M McGuire, et al.
Published: (2020-01-01)

Detection of cytomegalovirus (CMV) by digital PCR in stool samples for the non-invasive diagnosis of CMV gastroenteritis
by: Jia Gu, et al.
Published: (2022-11-01)

Valganciclovir for cytomegalovirus preemptive therapy in patients following allogeneic hematopoietic stem cell transplantation
by: LU Xuan, et al.
Published: (2020-09-01)

CMV genotyping using different samples in post renal transplant recipients with CMV disease
by: Ramya Barani, et al.
Published: (2017-10-01)

Cytomegalovirus infection of brain tumors and CMV immunotherapy
by: Mykola I. Lisianyi, et al.
Published: (2022-09-01)

Cytomegalovirus (CMV) seroprevalence in the adult population of Germany.
by: Raskit Lachmann, et al.
Published: (2018-01-01)

Preemptive screening strategies to identify postnatal CMV diseases on the neonatal unit.
by: Kadambari, S, et al.
Published: (2016)

ASSOCIATION OF SEROPOSITIVITY FOR CMV IGM AND IGG WITH ADVERSE PREGNANCY OUTCOME
by: Ambreen Amna, et al.
Published: (2021-06-01)

Latent Cytomegalovirus (CMV) Infection Does Not Detrimentally Alter T Cell Responses in the Healthy Old, But Increased Latent CMV Carriage Is Related to Expanded CMV-Specific T Cells
by: Sarah E. Jackson, et al.
Published: (2017-06-01)

Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant
by: Taeeun Kim, et al.
Published: (2020-03-01)

MONITORING OF CMV INFECTION IN KIDNEY TRANSPLANT RECIPIENTS
by: Zhivka Stoykova, et al.
Published: (2017-12-01)

CMV infection in post kidney transplant recipient
by: Abdelrahman Mohammed, et al.
Published: (2009-01-01)

Antiviral Treatment of Maternal and Congenital Cytomegalovirus (CMV) Infections
by: Swetha Pinninti, et al.
Published: (2023-10-01)

Successful Use of Heterologous CMV-Reactive T Lymphocyte to Treat Severe Refractory Cytomegalovirus (CMV) Infection in a Liver Transplanted Patient: Correlation of the Host Antiviral Immune Reconstitution with CMV Viral Load and CMV miRNome
by: Monica Miele, et al.
Published: (2021-03-01)

Cytomegalovirus (CMV)-Specific Perforin and Granzyme B ELISPOT Assays Detect Reactivation of CMV Infection in Inflammatory Bowel Disease
by: Paul V. Lehmann, et al.
Published: (2012-04-01)

Protective Cytomegalovirus (CMV)-Specific T-Cell Immunity Is Frequent in Kidney Transplant Patients without Serum Anti-CMV Antibodies
by: Nicolle H. R. Litjens, et al.
Published: (2017-09-01)

Kinetics of IgG antibody to cytomegalovirus (CMV) after birth and seroprevalence of anti-CMV IgG in Chinese children
by: Chen Jie, et al.
Published: (2012-12-01)

Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
by: Euri Seo, et al.
Published: (2021-01-01)

Utility of CMV-Specific Immune Monitoring for the Management of CMV in Solid Organ Transplant Recipients: A Clinical Update
by: Katya Prakash, et al.
Published: (2021-05-01)

Prevalence of asymptomatic cytomegalovirus (CMV) infection in newborns in northeast Florida
by: Rana Alissa, et al.
Published: (2024-01-01)

Human cytomegalovirus (CMV) dysregulates neurodevelopmental pathways in cerebral organoids
by: Ece Egilmezer, et al.
Published: (2024-03-01)

Highly quantitative serological detection of anti-cytomegalovirus (CMV) antibodies
by: Alter Harvey J, et al.
Published: (2009-05-01)

Human cytomegalovirus (CMV) in Africa: a neglected but important pathogen
by: Matthew Bates, et al.
Published: (2016-07-01)

Exciting Times for Cytomegalovirus (CMV) Vaccine Development: Navigating the Pathways toward the Goal of Protecting Infants against Congenital CMV Infection
by: Mark R. Schleiss, et al.
Published: (2020-09-01)

Genetically engineered live-attenuated cytomegalovirus (CMV) vaccines improve pregnancy outcome in the guinea-pig model of congenital CMV infection
by: Cui Xiaohong, et al.
Published: (2008-04-01)

Correction: Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
by: Euri Seo, et al.
Published: (2023-01-01)

The Impact of High CMV Viral Load and Refractory CMV Infection on Pediatric HSCT Recipients with Underlying Non-Malignant Disorder
by: Zofia Szmit, et al.
Published: (2022-09-01)

Droplet Digital PCR (ddPCR) Does Not Enhance the Sensitivity of Detection of Cytomegalovirus (CMV) DNA in Newborn Dried Blood Spots Evaluated in the Context of Newborn Congenital CMV (cCMV) Screening
by: Nelmary Hernandez-Alvarado, et al.
Published: (2023-12-01)